Words of Welcome

The EANM is pleased to announce its seventh Focus Meeting on the topic of Alzheimer’s disease, the most common neurodegenerative condition affecting billions of persons worldwide. The event will take place from February 5-7, 2026, in Palma de Mallorca, Spain.

Alzheimer’s disease is the most common neurodegenerative condition and a major global health and societal issue, concerning millions of persons worldwide and with a steadily increasing global prevalence in the aging population. For the first time since the disease definition, over a century ago, disease-specific treatments have been approved for use in multiple countries, including Europe.

With the motto of ‘An accurate diagnosis for an effective treatment with Molecular Imaging’, we invite you to join a multidisciplinary and international group of experts In a meeting known for a high level of live interaction and audience engagement. The group of panelists invited to contribute includes of representatives from some of the most important medical organizations that work on Alzheimer’s Disease.

During this upcoming Focus Meeting, we want to critically analyze the role of imaging in combination with other disease biomarkers, namely plasma and cerebrospinal fluid biomarkers in Alzheimer’s disease, by exploring the utility of nuclear medicine techniques in different clinical settings, especially: disease diagnosis and staging, differential diagnosis, selection of patients for targeted treatment, treatment monitoring and finally prevention. The aim of the meeting is to reach a final consensus on the most compelling indications for the use of nuclear medicine imaging in Alzheimer’s disease and to generate expert recommendations on how to best guide professionals in their clinical decisions, namely with respect of targeted treatments. As disease-specific treatments have finally become available, an accurate patient selection to maximise potential benefits and minimize risks and related costs is paramount.

Furthermore, new developments in radiopharmaceuticals under development for Alzheimer’s disease and related disorders will be discussed. Finally, we also intend to identify controversial topics and aspects with limited evidence, to provide specific action points to address them within this large and multidisciplinary network.

We are confident that, together, mirroring the fruitful exchanges that are symbolized by this mediterranean location, we will reach a collaborative consensus to ensure that patients suffering from Alzheimer’s disease will benefit of the most appropriate use of nuclear medicine.

Join us for the EANM Focus Meeting 7 from February 5-7, 2026, in Palma de Mallorca Spain!

Please note that registrations are limited to a maximum of 250 participants and will be allocated on a first-come, first-served basis. Make sure to sign up in a timely manner!
We look forward to welcoming you in Palma de Mallorca next year!

With kind regards,

Valentina Garibotto, Focus Meeting 7 Chair
Silvia Morbelli, Focus Meeting 7 Co-Chair
Nelleke Tolboom & Matthias Brendel, Focus Meeting 7 Scientific Programme Advisors